biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 16/2022 | 15-09-2022 | Otrzymanie wstrzymanej części Ceny Nabycia 100% udziałów Curiosity Diagnostics sp. z o.o.

Previous PostNext Post

Related Posts

01.04.2025

Scope Fluidics Named “Stock Exchange Company of the Year 2024″ by Puls Biznesu

0
08.01.2025

Scope Fluidics Reports Positive Results from Software Development for Rapid Detection

0
08.01.2025

EAP Results Confirm Readiness for BACTEROMIC System Market Deployment

0